US health insurance plans comment on CDC clinical practice guidelines for prescribing opioids – InsuranceNewsNet


WASHINGTON, April 12 (TNSPol) — US health insurance plans issued the following press release:

Every American deserves comprehensive, affordable coverage that gives them access to equitable, high-quality care — care that helps them avoid the dangers of inappropriate opioid prescribing. With this commitment, AHIP submitted comments on the 2022 draft CDC Clinical practice guideline for prescribing opioids. Here are the highlights.

We all have a part to play

“The opioid crisis is devastating to its victims, their families, and communities across the country. Sadly, opioid overdose deaths continue to rise. In order to move forward and reverse this devastating trend, the opioid crisis must be approached holistically, This includes local governments, law enforcement and the justice system, social service agencies, community housing programs, Medicaid programs, physicians and other health care providers, pharmacists, health insurance providers and pharmaceutical companies.

Health insurance providers are part of the solution

“Health insurance providers have long been part of the solution by working closely with clinicians and other stakeholders and taking a comprehensive, evidence-based approach encompassing prevention, early intervention and treatment. and recovery from substance use disorders.”

“Health insurance providers will continue to work to address the opioid crisis and collaborate with other stakeholders to protect patient safety and improve outcomes. The strategies and challenges outlined in the guideline provide a constructive shift toward person-centred, evidence-based care we support CDC‘s findings.”

AHIP supports human-centric solutions

“We support the guideline’s goals of improving communication between clinicians and patients and empowering them to make informed, person-centered decisions about pain care.”

“We particularly appreciate the increased focus on a patient’s treatment needs and goals.”

“We support the proposed inclusion of social and other non-clinical factors in the new guideline, as well as the attention to equity issues.”

A call for more evidence

“Finally, we support calls for new research to fill knowledge gaps associated with opioid prescribing, dosages and risk factors; multidisciplinary models of pain management; alternative therapies and assessment of painless outcomes; diagnoses; care transitions; and impacts of AHIP and its members agree that there is a need for research to improve existing risk assessment tools and to inform future guidelines evidence-based clinics on dosing and treatment options to manage various types of pain.

The comment letter also includes recommendations for additional clarifications and considerations to be incorporated into the guideline.

Read the comment letter (


About Author

Comments are closed.